- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01273597
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary
Przegląd badań
Status
Warunki
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Budapest, Węgry, 1083
- Site Reference ID/Investigator# 46593
-
Budapest, Węgry, 1115
- Site Reference ID/Investigator# 46585
-
Debrecen, Węgry, 4012
- Site Reference ID/Investigator# 46594
-
Gyor, Węgry, 9023
- Site Reference ID/Investigator# 47722
-
Karcag, Węgry, 5301
- Site Reference ID/Investigator# 46592
-
Karcag, Węgry, 5301
- Site Reference ID/Investigator# 58644
-
Miskolc, Węgry, 3501
- Site Reference ID/Investigator# 46595
-
Nyiregyhaza, Węgry, 4400
- Site Reference ID/Investigator# 46588
-
Pecs, Węgry, 7624
- Site Reference ID/Investigator# 46597
-
Szombathely, Węgry, 9700
- Site Reference ID/Investigator# 46590
-
Veszprem, Węgry, 8200
- Site Reference ID/Investigator# 46591
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
Based on the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection), the patient is entitled to treatment with paricalcitol injection and:
- ≥ 18 years of age,
- Willing to sign the patient information and informed consent form,
Chronic kidney disease (CKD) stage 5 patient receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT), whose intact parathyroid hormone (iPTH) level is:
- between 500-800 pg/mL with at least two abruption of conventional vitamin D therapy due to elevated serum calcium level (i.e. > 2.4 mmol/L) in the medical history, or
- higher than 800 pg/mL and parathyroidectomy is contraindicated.
- The patient is planned to receive paricalcitol treatment independently from his/her participation in this study.
Exclusion Criteria:
Patients cannot be enrolled in the study if any of the following exclusion criteria apply:
- The patient is already treated with Zemplar (paricalcitol injection),
- Any contraindication exists as stated in the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection),
- Patients who decline to participate in the study or decline to sign the patient information/informed consent form.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
End-stage kidney disease with secondary hyperparathyroidism
Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)
Ramy czasowe: 6 months
|
Maintenance dose is defined as weekly dose of paricalcitol that results in at least 2 consecutive intact parathyroid hormone (iPTH) values within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants Achieving Target Intact Parathyroid Hormone (iPTH) Levels at Month 6
Ramy czasowe: 6 months
|
Target intact parathyroid hormone (iPTH) values were within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.
|
6 months
|
Country-Specific Data on the Usage of Medication Affecting Calcium (Ca) Balance
Ramy czasowe: 6 months prior to start of study through 6 months of treatment
|
If available, data on vitamin D treatment (those who received vitamin D supplement products from Anatomical Therapeutic Chemical [ATC] group A11CC [vitamin D and analogues]) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
|
6 months prior to start of study through 6 months of treatment
|
Country-Specific Data on the Usage of Medication Affecting Phosphorus (P) Balance
Ramy czasowe: 6 months prior to start of study through 6 months of treatment
|
If available, data on the use of phosphate binders (those who received calcium-based phosphate binders or sevelamer/lanthanum) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
|
6 months prior to start of study through 6 months of treatment
|
Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism
Ramy czasowe: 6 months prior to start of study through 6 months of treatment
|
If available, data on the use of medication affecting secondary hyperparathyroidism (those who received calcimimetics and calcium supplementation) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
|
6 months prior to start of study through 6 months of treatment
|
Number of Participants With Hypercalcaemia During Preceding 6 Months of Conventional Vitamin D Therapy
Ramy czasowe: 6 months prior to start of study through baseline
|
Hypercalcaemia (serum calcium > 2.6 mmol/L) among participants during the preceding 6 months of conventional vitamin D therapy was derived from retrospective data collection in case report form, reported at baseline.
Conventional vitamin D therapy included vitamin D supplement products from ATC group A11CC (vitamin D and analogues).
|
6 months prior to start of study through baseline
|
Number of Participants With Hypercalcaemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment
Ramy czasowe: 6 months
|
Hypercalcaemia (serum calcium > 2.6 mmol/L), based on laboratory data, was collected during the observed 6 months treatment with Zemplar (paricalcitol injection).
|
6 months
|
Number of Participants With Hyperphosphataemia During Preceding Conventional Vitamin D Therapy
Ramy czasowe: 6 months prior to start of study through baseline
|
Hyperphosphataemia (serum phosphorus >1.78 mmol/L) among participants during the preceding 6 months of conventional vitamin D therapy was derived from retrospective data collection in case report form, reported at baseline.
Conventional vitamin D therapy included vitamin D supplement products from ATC group A11CC (vitamin D and analogues).
|
6 months prior to start of study through baseline
|
Number of Participants With Hyperphosphataemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment
Ramy czasowe: 6 months
|
Hyperphosphataemia (serum phosphorus > 1.78 mmol/L), based on laboratory data, was collected during the observed 6 months treatment with Zemplar (paricalcitol injection).
|
6 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Tamas Schnaider, AbbVie (prior sponsor, Abbott)
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- P12-644
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .